Max Healthcare Inst.
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Aug 20 (Reuters) - Indian hospital operator Manipal Health Enterprises MNIA.NS on Thursday reported a nearly 31% rise in adjusted first-quarter profit after tax, driven by strong demand for complex procedures and higher hospital occupancy.
The company posted an adjusted consolidated profit after tax of 3.32 billion rupees ($34.69 million) for the quarter ended June 30, up from 2.54 billion rupees a year earlier.
The results mark the hospital operator's first quarterly earnings report since its $960 million initial public offering in July.
Overall quarterly revenue rose 38.1% to 30.91 billion rupees, boosted by higher patient volumes and an increasing share of high-value specialty procedures, which have supported earnings across the sector in recent quarters.
Indian hospital operators have also been expanding aggressively through acquisitions of smaller hospitals and capacity additions, particularly in smaller cities, to capitalize on growing demand for healthcare services.
The company's consolidated net profit fell 7.5% to 2.32 billion rupees from a year earlier, due to costs related to the acquisition of Sahyadri Hospitals. Manipal Health had acquired a majority stake in the Maharashtra-based company in late 2025.
"The integration of Sahyadri Hospitals remains a key priority as we unlock the benefits of a larger network and greater operating scale. Our IPO provides greater flexibility to invest in capacity, technology and clinical excellence while maintaining disciplined capital allocation," MD and CEO Dileep Jose said.
Quarterly expenses rose 47.4% from a year earlier to 28.35 billion rupees, impacted by a rise in the purchase of pharmacy items and other expenses.
($1 = 95.7050 Indian rupees)
(Reporting by Kashish Tandon and Mridula Kumar in Bengaluru; Editing by Janane Venkatraman and Jonathan Ananda)
(([email protected]; 8800437922;))
Aug 20 (Reuters) - Indian hospital operator Manipal Health Enterprises MNIA.NS on Thursday reported a nearly 31% rise in adjusted first-quarter profit after tax, driven by strong demand for complex procedures and higher hospital occupancy.
The company posted an adjusted consolidated profit after tax of 3.32 billion rupees ($34.69 million) for the quarter ended June 30, up from 2.54 billion rupees a year earlier.
The results mark the hospital operator's first quarterly earnings report since its $960 million initial public offering in July.
Overall quarterly revenue rose 38.1% to 30.91 billion rupees, boosted by higher patient volumes and an increasing share of high-value specialty procedures, which have supported earnings across the sector in recent quarters.
Indian hospital operators have also been expanding aggressively through acquisitions of smaller hospitals and capacity additions, particularly in smaller cities, to capitalize on growing demand for healthcare services.
The company's consolidated net profit fell 7.5% to 2.32 billion rupees from a year earlier, due to costs related to the acquisition of Sahyadri Hospitals. Manipal Health had acquired a majority stake in the Maharashtra-based company in late 2025.
"The integration of Sahyadri Hospitals remains a key priority as we unlock the benefits of a larger network and greater operating scale. Our IPO provides greater flexibility to invest in capacity, technology and clinical excellence while maintaining disciplined capital allocation," MD and CEO Dileep Jose said.
Quarterly expenses rose 47.4% from a year earlier to 28.35 billion rupees, impacted by a rise in the purchase of pharmacy items and other expenses.
($1 = 95.7050 Indian rupees)
(Reporting by Kashish Tandon and Mridula Kumar in Bengaluru; Editing by Janane Venkatraman and Jonathan Ananda)
(([email protected]; 8800437922;))
Aug 13 (Reuters) - Max Healthcare Institute Limited MAXE.NS:
Q1 CONSOL REVENUE FROM OPERATIONS 23.66 BILLION RUPEES; IBES EST. 27.5 BILLION RUPEES
Q1 CONSOL NET PROFIT 3.22 BILLION RUPEES; IBES EST. 3.99 BILLION RUPEES
APPROVES 4.25 BLN RUPEES CAPEX FOR TOWER 3 AT MAX SUPER SPECIALITY HOSPITAL VAISHALI
BOARD GIVES IN-PRINCIPLE APPROVAL TO EXPLORE SETTING UP MEDICAL COLLEGES OR INSTITUTIONS
Further company coverage: MAXE.NS
(([email protected];;))
Aug 13 (Reuters) - Max Healthcare Institute Limited MAXE.NS:
Q1 CONSOL REVENUE FROM OPERATIONS 23.66 BILLION RUPEES; IBES EST. 27.5 BILLION RUPEES
Q1 CONSOL NET PROFIT 3.22 BILLION RUPEES; IBES EST. 3.99 BILLION RUPEES
APPROVES 4.25 BLN RUPEES CAPEX FOR TOWER 3 AT MAX SUPER SPECIALITY HOSPITAL VAISHALI
BOARD GIVES IN-PRINCIPLE APPROVAL TO EXPLORE SETTING UP MEDICAL COLLEGES OR INSTITUTIONS
Further company coverage: MAXE.NS
(([email protected];;))
Updates with comments from company and IPO details
By Rishika Sadam and Vivek Kumar M
July 24 (Reuters) - India's Manipal Health Enterprises MNIA.NS plans to spend 40 billion rupees ($414.38 million) to increase its bed capacity by over 18% in the next few years, a company executive said on Friday, ahead of the launch of the hospital chain operator's IPO next week.
The Temasek-backed company, one of India's largest hospital chain operators, plans to add 2,400 beds to its existing 13,037 capacity within three to four years, Dilip Jose, managing director and CEO at Manipal Health Enterprises, said in a press conference.
The Bengaluru-based chain operates 49 hospitals across India and competes with the likes of Apollo Hospitals Enterprise APLH.NS, Max Healthcare MAXE.NS, and Fortis Healthcare FOHE.NS.
The company is also targeting a valuation of up to $8 billion for its $960.4 million IPO, India's second-largest primary market offering this year after SBI Funds Management's SBIA.NS $1.03 billion issue earlier this month.
Manipal Health plans to issue new shares worth $828.4 million in the IPO. Existing investors including Temasek's unit Imperius Healthcare Investments and TPG Capital will offload shares worth $132 million.
The hospital chain operator said it expects to turn net debt-free with the help of the IPO proceeds.
Anchor investors can bid for Manipal Health's shares by July 28. Public subscription will be open from July 29 to July 31.
($1 = 96.5725 Indian rupees)
(Reporting by Vivek Kumar M in Bengaluru and Rishika Sadam in Hyderabad; Editing by Mrigank Dhaniwala, Sherry Jacob-Phillips and Sonia Cheema)
(([email protected];))
Updates with comments from company and IPO details
By Rishika Sadam and Vivek Kumar M
July 24 (Reuters) - India's Manipal Health Enterprises MNIA.NS plans to spend 40 billion rupees ($414.38 million) to increase its bed capacity by over 18% in the next few years, a company executive said on Friday, ahead of the launch of the hospital chain operator's IPO next week.
The Temasek-backed company, one of India's largest hospital chain operators, plans to add 2,400 beds to its existing 13,037 capacity within three to four years, Dilip Jose, managing director and CEO at Manipal Health Enterprises, said in a press conference.
The Bengaluru-based chain operates 49 hospitals across India and competes with the likes of Apollo Hospitals Enterprise APLH.NS, Max Healthcare MAXE.NS, and Fortis Healthcare FOHE.NS.
The company is also targeting a valuation of up to $8 billion for its $960.4 million IPO, India's second-largest primary market offering this year after SBI Funds Management's SBIA.NS $1.03 billion issue earlier this month.
Manipal Health plans to issue new shares worth $828.4 million in the IPO. Existing investors including Temasek's unit Imperius Healthcare Investments and TPG Capital will offload shares worth $132 million.
The hospital chain operator said it expects to turn net debt-free with the help of the IPO proceeds.
Anchor investors can bid for Manipal Health's shares by July 28. Public subscription will be open from July 29 to July 31.
($1 = 96.5725 Indian rupees)
(Reporting by Vivek Kumar M in Bengaluru and Rishika Sadam in Hyderabad; Editing by Mrigank Dhaniwala, Sherry Jacob-Phillips and Sonia Cheema)
(([email protected];))
May 21 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
APPROVES CONSTRUCTION OF PHASE-I MAX SUPER SPECIALTY HOSPITAL IN LUCKNOW WITH 712 BEDS
CONSTRUCTION EQUIPMENT COST FOR PHASE-I EXPECTED TO BE 14 BILLION RUPEES
Source text: ID:nNSE4b9gVc
Further company coverage: MAXE.NS
(([email protected];))
May 21 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
APPROVES CONSTRUCTION OF PHASE-I MAX SUPER SPECIALTY HOSPITAL IN LUCKNOW WITH 712 BEDS
CONSTRUCTION EQUIPMENT COST FOR PHASE-I EXPECTED TO BE 14 BILLION RUPEES
Source text: ID:nNSE4b9gVc
Further company coverage: MAXE.NS
(([email protected];))
May 18 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
MAX HEALTHCARE INSTITUTE LTD - BUYS 58.28% EQUITY STAKE IN KALINGA HOSPITAL FOR 2.98 BILLION RUPEES
Source text: ID:nNSE425Fyx
Further company coverage: MAXE.NS
(([email protected];;))
May 18 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
MAX HEALTHCARE INSTITUTE LTD - BUYS 58.28% EQUITY STAKE IN KALINGA HOSPITAL FOR 2.98 BILLION RUPEES
Source text: ID:nNSE425Fyx
Further company coverage: MAXE.NS
(([email protected];;))
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Ujjaini Dutta
BENGALURU, April 13 (Reuters Breakingviews) - Feverish demand for private medical care in India will aid Temasek as it lines up a $1.2 billion initial public offering of Manipal Hospitals, the country's largest chain with 12,000 beds. Yet at a mooted $13 billion valuation, the Singapore sovereign investor may be stretching too far to crystallise a strong exit on one of its rare controlling stakes.
Its 51% holding in Manipal is part of Temasek’s S$434 billion ($324 billion) global portfolio which boasts a growing footprint in India. The South Asian country accounts for about 8% of underlying assets, up from 5% a decade ago. Its exposure could rise higher in the coming years under Piyush Gupta; in November, Temasek appointed the former DBS Group DBSM.SI chief executive as its India chair. Manipal’s listing hands the bank its first IPO mandate in India.
The Singaporean investment firm valued the company at just under $5 billion in 2023 when it picked up a 41% stake for $2 billion. At the time, Manipal founder and Chair Ranjan Pai said the business needed "long-term patient capital". It has acquired five hospital brands since Temasek first invested in it in 2017. Meanwhile, revenue is set to grow 27% in the financial year to the end of March 2026, based on annualising results in the six months to the end of September in its IPO prospectus, with a 6% net profit margin.
At a time when global investors are cooling on Indian equities, it helps that Manipal's footprint is concentrated in the southern states where incomes are higher and patients older. Even so, the targeted headline valuation for the hospital chain would value it at 107 times its annualised first-half earnings, Breakingviews calculates, nearly double the multiple of its top three rivals Apollo Hospitals APLH.NS, Fortis Healthcare FOHE.NS and Max Healthcare MAXE.NS. Manipal is more efficient than its rivals yet its average revenue per bed is only about 5% higher than Apollo Hospitals' and 4% higher than Fortis Healthcare.
True, hospital valuations have swung wildly in India, with Apollo's nearly halving from two years ago but Temasek doesn't need such a grand debut for its bet on Manipal to stack up, and forcing one could cast a shadow over its ambitions to increase its exposure to the country.
Follow Ujjaini Dutta on LinkedIn and X
CONTEXT NEWS
India's Manipal Health Enterprises filed for an up to $1.17 billion initial public offering on March 23. The initial public offering comprises a fresh issue to raise $852.2 million and an offer for sale by existing investors including Singapore's Temasek, U.S. investment firm TPG, Manipal Education and Novo Holdings, according to its draft prospectus.
The company is targeting a valuation of up to $13 billion, Bloomberg reported on March 24, citing people familiar with the matter.
Manipal has expanded quickly via acquisitions since 2021 https://www.reuters.com/graphics/BRV-BRV/byprnxyrnpe/chart.png
(Editing by Una Galani; Production by Aditya Srivastav)
((For previous columns by the author, Reuters customers can click on DUTTA/[email protected]))
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Ujjaini Dutta
BENGALURU, April 13 (Reuters Breakingviews) - Feverish demand for private medical care in India will aid Temasek as it lines up a $1.2 billion initial public offering of Manipal Hospitals, the country's largest chain with 12,000 beds. Yet at a mooted $13 billion valuation, the Singapore sovereign investor may be stretching too far to crystallise a strong exit on one of its rare controlling stakes.
Its 51% holding in Manipal is part of Temasek’s S$434 billion ($324 billion) global portfolio which boasts a growing footprint in India. The South Asian country accounts for about 8% of underlying assets, up from 5% a decade ago. Its exposure could rise higher in the coming years under Piyush Gupta; in November, Temasek appointed the former DBS Group DBSM.SI chief executive as its India chair. Manipal’s listing hands the bank its first IPO mandate in India.
The Singaporean investment firm valued the company at just under $5 billion in 2023 when it picked up a 41% stake for $2 billion. At the time, Manipal founder and Chair Ranjan Pai said the business needed "long-term patient capital". It has acquired five hospital brands since Temasek first invested in it in 2017. Meanwhile, revenue is set to grow 27% in the financial year to the end of March 2026, based on annualising results in the six months to the end of September in its IPO prospectus, with a 6% net profit margin.
At a time when global investors are cooling on Indian equities, it helps that Manipal's footprint is concentrated in the southern states where incomes are higher and patients older. Even so, the targeted headline valuation for the hospital chain would value it at 107 times its annualised first-half earnings, Breakingviews calculates, nearly double the multiple of its top three rivals Apollo Hospitals APLH.NS, Fortis Healthcare FOHE.NS and Max Healthcare MAXE.NS. Manipal is more efficient than its rivals yet its average revenue per bed is only about 5% higher than Apollo Hospitals' and 4% higher than Fortis Healthcare.
True, hospital valuations have swung wildly in India, with Apollo's nearly halving from two years ago but Temasek doesn't need such a grand debut for its bet on Manipal to stack up, and forcing one could cast a shadow over its ambitions to increase its exposure to the country.
Follow Ujjaini Dutta on LinkedIn and X
CONTEXT NEWS
India's Manipal Health Enterprises filed for an up to $1.17 billion initial public offering on March 23. The initial public offering comprises a fresh issue to raise $852.2 million and an offer for sale by existing investors including Singapore's Temasek, U.S. investment firm TPG, Manipal Education and Novo Holdings, according to its draft prospectus.
The company is targeting a valuation of up to $13 billion, Bloomberg reported on March 24, citing people familiar with the matter.
Manipal has expanded quickly via acquisitions since 2021 https://www.reuters.com/graphics/BRV-BRV/byprnxyrnpe/chart.png
(Editing by Una Galani; Production by Aditya Srivastav)
((For previous columns by the author, Reuters customers can click on DUTTA/[email protected]))
April 8 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
APPROVES ACQUISITION OF 58.39% CONTROLLING STAKE IN KALINGA HOSPITAL LTD
APPROVES LOANS UP TO 1 BILLION RUPEES TO KALINGA HOSPITAL LTD
TO BUY 58.4% STAKE IN KALINGA HOSPITAL AT EQUITY VALUE OF 3 BILLION RUPEES
APPROVES SENIOR SECURED TERM LOAN UP TO 3 BILLION RUPEES FOR ACQUISITION FINANCING
Source text: ID:nBSE8scTm9
Further company coverage: MAXE.NS
(([email protected];;))
April 8 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
APPROVES ACQUISITION OF 58.39% CONTROLLING STAKE IN KALINGA HOSPITAL LTD
APPROVES LOANS UP TO 1 BILLION RUPEES TO KALINGA HOSPITAL LTD
TO BUY 58.4% STAKE IN KALINGA HOSPITAL AT EQUITY VALUE OF 3 BILLION RUPEES
APPROVES SENIOR SECURED TERM LOAN UP TO 3 BILLION RUPEES FOR ACQUISITION FINANCING
Source text: ID:nBSE8scTm9
Further company coverage: MAXE.NS
(([email protected];;))
Feb 5 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
Q3 CONSOL PROFIT 3.01 BILLION RUPEES
Q3 CONSOL REV FROM OPS 20.68 BLN RUPEES
AMENDMENT TO PACT TO ADD BEDS AT MAX SUPER SPECIALITY HOSPITAL, DWARKA
PROPOSED ADDITION OF 260 BEDS AT MAX DWARKA
Further company coverage: MAXE.NS
(([email protected];;))
Feb 5 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
Q3 CONSOL PROFIT 3.01 BILLION RUPEES
Q3 CONSOL REV FROM OPS 20.68 BLN RUPEES
AMENDMENT TO PACT TO ADD BEDS AT MAX SUPER SPECIALITY HOSPITAL, DWARKA
PROPOSED ADDITION OF 260 BEDS AT MAX DWARKA
Further company coverage: MAXE.NS
(([email protected];;))
Aug 22 (Reuters) - Interglobe Aviation Ltd INGL.NS:
NSE: MAX HEALTHCARE AND INTERGLOBE AVIATION TO BE INCLUDED IN NIFTY 50
NSE: INDUSIND BANK AND HERO MOTOCORP TO BE EXCLUDED FROM NIFTY 50
NSE: CHANGES IN NIFTY 50 SHALL BECOME EFFECTIVE FROM SEPTEMBER 30
Further company coverage: INGL.NS
(([email protected];))
Aug 22 (Reuters) - Interglobe Aviation Ltd INGL.NS:
NSE: MAX HEALTHCARE AND INTERGLOBE AVIATION TO BE INCLUDED IN NIFTY 50
NSE: INDUSIND BANK AND HERO MOTOCORP TO BE EXCLUDED FROM NIFTY 50
NSE: CHANGES IN NIFTY 50 SHALL BECOME EFFECTIVE FROM SEPTEMBER 30
Further company coverage: INGL.NS
(([email protected];))
March 14 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
UPDATES ON MATTER AGAINST COMPETITION COMMISSION OF INDIA
WITHDRAWS WRIT PETITION CHALLENGING ORDER OF CCI
Source text: ID:nBSE9bhFwW
Further company coverage: MAXE.NS
(([email protected];;))
March 14 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
UPDATES ON MATTER AGAINST COMPETITION COMMISSION OF INDIA
WITHDRAWS WRIT PETITION CHALLENGING ORDER OF CCI
Source text: ID:nBSE9bhFwW
Further company coverage: MAXE.NS
(([email protected];;))
March 12 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
TO ENTER INTO AGREEMENT WITH BHARAT PRAKRITIK CHIKITSA MISSION
CONSTRUCTION OF HOSPITAL PREMISES EXPECTED TO BE COMPLETED IN NEXT 3-4 YRS
Source text: ID:nBSE7FVq1s
Further company coverage: MAXE.NS
(([email protected];;))
March 12 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
TO ENTER INTO AGREEMENT WITH BHARAT PRAKRITIK CHIKITSA MISSION
CONSTRUCTION OF HOSPITAL PREMISES EXPECTED TO BE COMPLETED IN NEXT 3-4 YRS
Source text: ID:nBSE7FVq1s
Further company coverage: MAXE.NS
(([email protected];;))
July 16 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
MAX HEALTHCARE INSTITUTE - UNIT GOT TAX ORDER FOR PENALTY OF 61.6 MILLION RUPEES
Source text for Eikon: ID:nNSE5Z1LfJ
Further company coverage: MAXE.NS
(([email protected];))
July 16 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
MAX HEALTHCARE INSTITUTE - UNIT GOT TAX ORDER FOR PENALTY OF 61.6 MILLION RUPEES
Source text for Eikon: ID:nNSE5Z1LfJ
Further company coverage: MAXE.NS
(([email protected];))
May 22 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
Q4 CONSOL PROFIT 2.52 BILLION RUPEES; LSEG IBES PROFIT EST. 3.62 BILLION RUPEES
APPROVED AN OVERALL SPEND OF UPTO 10.38 BILLION RUPEES TOWARDS CONSTRUCTION OF GURUGRAM HOSPITAL
Q4 CONSOL REVENUE FROM OPERATIONS 14.23 BILLION RUPEES; LSEG IBES EST. 18.04 BILLION RUPEES
YEAR AGO Q4 CONSOL PROFIT 2.51 BILLION RUPEES; REVENUE 12.15 BILLION RUPEES
APPROVED OVERALL SPEND OF UPTO 3.76 BILLION RUPEES TOWARD EXPANSION OF MOHALI HOSPITAL
DIVIDEND OF 1.5 RUPEES PER SHR
Source text for Eikon: ID:nBSEc0tmzz
Further company coverage: MAXE.NS
(([email protected];))
May 22 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
Q4 CONSOL PROFIT 2.52 BILLION RUPEES; LSEG IBES PROFIT EST. 3.62 BILLION RUPEES
APPROVED AN OVERALL SPEND OF UPTO 10.38 BILLION RUPEES TOWARDS CONSTRUCTION OF GURUGRAM HOSPITAL
Q4 CONSOL REVENUE FROM OPERATIONS 14.23 BILLION RUPEES; LSEG IBES EST. 18.04 BILLION RUPEES
YEAR AGO Q4 CONSOL PROFIT 2.51 BILLION RUPEES; REVENUE 12.15 BILLION RUPEES
APPROVED OVERALL SPEND OF UPTO 3.76 BILLION RUPEES TOWARD EXPANSION OF MOHALI HOSPITAL
DIVIDEND OF 1.5 RUPEES PER SHR
Source text for Eikon: ID:nBSEc0tmzz
Further company coverage: MAXE.NS
(([email protected];))
Repeats for wider distribution with no changes to text
MUMBAI/BENGALURU, May 6 (Reuters) - Global investment firm KKR KKR.N will buy Indian medical devices maker Healthium Medtech HEAT.NS from UK-based Apax Partners in a deal that three sources with direct knowledge of the matter say is valued at 70 billion rupees ($838.60 million).
Healthium and Apax did not immediately respond to Reuters' requests seeking comment, while KKR declined to comment.
KKR will acquire Healthium through a special purpose vehicle - owned by KKR-managed funds - that will have a controlling interest in Healthium group, including Healthium Medtech, the three companies said in a statement.
The acquisition marks KKR's latest investment in the Indian healthcare sector, with the firm already holding stakes in Indian drugmaker J B Chemicals and Pharmaceuticals JBCH.NS, hospital chain operator Max Healthcare MAXE.NS and generic injectables maker Gland Pharma GLAD.NS.
Private equity firm Apax bought Healthium, which is involved in the manufacturing of products used in surgical, post-surgical, and chronic care procedures, in 2018.
($1 = 83.4725 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru, M. Sriram in Mumbai, Kane Wu in Hong Kong; Editing by Janane Venkatraman )
(([email protected]; 8800437922;))
Repeats for wider distribution with no changes to text
MUMBAI/BENGALURU, May 6 (Reuters) - Global investment firm KKR KKR.N will buy Indian medical devices maker Healthium Medtech HEAT.NS from UK-based Apax Partners in a deal that three sources with direct knowledge of the matter say is valued at 70 billion rupees ($838.60 million).
Healthium and Apax did not immediately respond to Reuters' requests seeking comment, while KKR declined to comment.
KKR will acquire Healthium through a special purpose vehicle - owned by KKR-managed funds - that will have a controlling interest in Healthium group, including Healthium Medtech, the three companies said in a statement.
The acquisition marks KKR's latest investment in the Indian healthcare sector, with the firm already holding stakes in Indian drugmaker J B Chemicals and Pharmaceuticals JBCH.NS, hospital chain operator Max Healthcare MAXE.NS and generic injectables maker Gland Pharma GLAD.NS.
Private equity firm Apax bought Healthium, which is involved in the manufacturing of products used in surgical, post-surgical, and chronic care procedures, in 2018.
($1 = 83.4725 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru, M. Sriram in Mumbai, Kane Wu in Hong Kong; Editing by Janane Venkatraman )
(([email protected]; 8800437922;))
March 12 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
CO, TOUCH HEALTHCARE AND OTHERS HAVE ENTERED INTO AN AGREEMENT
AGREEMENT IN RESPECT OF THE ONGOING ARBITRATION PROCEEDINGS BETWEEN THE PARTIES
PURSUANT TO AGREEMENT SAID ARBITRATION PROCEEDINGS HAVE BEEN DISCONTINUED
Further company coverage: MAXE.NS
(([email protected];))
March 12 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
CO, TOUCH HEALTHCARE AND OTHERS HAVE ENTERED INTO AN AGREEMENT
AGREEMENT IN RESPECT OF THE ONGOING ARBITRATION PROCEEDINGS BETWEEN THE PARTIES
PURSUANT TO AGREEMENT SAID ARBITRATION PROCEEDINGS HAVE BEEN DISCONTINUED
Further company coverage: MAXE.NS
(([email protected];))
Jan 31 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
APPROVED TO ACQUIRE ADDITIONAL EQUITY STAKE OF 3.6% IN SANDHYA HYDRO POWER PROJECTS BALARGHA
Q3 CONSOL PROFIT 2.89 BILLION RUPEES; LSEG IBES EST. 3.32 BILLION RUPEES
Q3 CONSOL REVENUE FROM OPERATIONS 13.35 BILLION RUPEES
YEAR AGO Q3 CONSOL PROFIT 2.22 BILLION RUPEES; REVENUE 11.42 BILLION RUPEES
APPROVED TO ACQUIRE ADDITIONAL EQUITY STAKE OF 3.6% IN SANDHYA HYDRO POWER PROJECTS BALARGHA
COST OF ACQUISITION AT 8.5 MILLION RUPEES
Source text for Eikon: ID:nBSE1y5fJK
Further company coverage: MAXE.NS
(([email protected];))
Jan 31 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
APPROVED TO ACQUIRE ADDITIONAL EQUITY STAKE OF 3.6% IN SANDHYA HYDRO POWER PROJECTS BALARGHA
Q3 CONSOL PROFIT 2.89 BILLION RUPEES; LSEG IBES EST. 3.32 BILLION RUPEES
Q3 CONSOL REVENUE FROM OPERATIONS 13.35 BILLION RUPEES
YEAR AGO Q3 CONSOL PROFIT 2.22 BILLION RUPEES; REVENUE 11.42 BILLION RUPEES
APPROVED TO ACQUIRE ADDITIONAL EQUITY STAKE OF 3.6% IN SANDHYA HYDRO POWER PROJECTS BALARGHA
COST OF ACQUISITION AT 8.5 MILLION RUPEES
Source text for Eikon: ID:nBSE1y5fJK
Further company coverage: MAXE.NS
(([email protected];))
Adds details of the deal, recent hospital mergers in India
BENGALURU, Dec 8 (Reuters) - India's Max Healthcare Institute MAXE.NS said on Friday it would buy Sahara Hospital in Lucknow, Uttar Pradesh for an enterprise value of 9.40 billion rupees ($112.76 million), as it looks to expand its operations in the country.
The 550-bed Sahara Hospital treats about 200,000 patients every year and has a revenue potential of 2 billion rupees for fiscal 2024, Max Healthcare said in a statement.
The company, which has 17 healthcare facilities mostly concentrated in North India, said Sahara Hospital has the potential to quickly ramp up beds and expand medical programs such as oncology and transplants.
Deals in Indian hospitals space have heated up, with mergers and acquisitions totalling $4 billion in 2022 and $2.2 billion in the first five months of this year.
Global consultancy firm PwC projects 12%-14% annual growth for the country's private healthcare market, which has seen a post-pandemic boom.
Indian hospital chain operator Manipal Hospitals in September acquired an 84% stake in AMRI Hospitals in its bid to expand its presence in eastern India, while private equity firm Blackstone BX.N in October said it would buy a majority stake in India's Care Hospitals.
($1 = 83.3650 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru; Editing by Nivedita Bhattacharjee and Shilpi Majumdar)
(([email protected]; +91 7982114624;))
Adds details of the deal, recent hospital mergers in India
BENGALURU, Dec 8 (Reuters) - India's Max Healthcare Institute MAXE.NS said on Friday it would buy Sahara Hospital in Lucknow, Uttar Pradesh for an enterprise value of 9.40 billion rupees ($112.76 million), as it looks to expand its operations in the country.
The 550-bed Sahara Hospital treats about 200,000 patients every year and has a revenue potential of 2 billion rupees for fiscal 2024, Max Healthcare said in a statement.
The company, which has 17 healthcare facilities mostly concentrated in North India, said Sahara Hospital has the potential to quickly ramp up beds and expand medical programs such as oncology and transplants.
Deals in Indian hospitals space have heated up, with mergers and acquisitions totalling $4 billion in 2022 and $2.2 billion in the first five months of this year.
Global consultancy firm PwC projects 12%-14% annual growth for the country's private healthcare market, which has seen a post-pandemic boom.
Indian hospital chain operator Manipal Hospitals in September acquired an 84% stake in AMRI Hospitals in its bid to expand its presence in eastern India, while private equity firm Blackstone BX.N in October said it would buy a majority stake in India's Care Hospitals.
($1 = 83.3650 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru; Editing by Nivedita Bhattacharjee and Shilpi Majumdar)
(([email protected]; +91 7982114624;))
Nov 6 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
SEPT-QUARTER CONSOL PROFIT 2.77 BILLION RUPEES; LSEG IBES EST. 3.24 BILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 13.63 BILLION RUPEES
YEAR AGO SEPT-QUARTER CONSOL PROFIT 4.57 BILLION RUPEES; REVENUE 11.39 BILLION RUPEES
Source text for Eikon: ID:nBSE2KwTy0
Further company coverage: MAXE.NS
(([email protected];))
Nov 6 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
SEPT-QUARTER CONSOL PROFIT 2.77 BILLION RUPEES; LSEG IBES EST. 3.24 BILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 13.63 BILLION RUPEES
YEAR AGO SEPT-QUARTER CONSOL PROFIT 4.57 BILLION RUPEES; REVENUE 11.39 BILLION RUPEES
Source text for Eikon: ID:nBSE2KwTy0
Further company coverage: MAXE.NS
(([email protected];))
Aug 7 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
INDIA'S MAX HEALTHCARE INSTITUTE JUNE-QUARTER CONSOL PROFIT 2.4 BILLION RUPEES VERSUS 1.73 BILLION RUPEES
MAX HEALTHCARE INSTITUTE JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 12.85 BILLION RUPEES VERSUS 10.67 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: MAXE.NS
(([email protected];))
Aug 7 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
INDIA'S MAX HEALTHCARE INSTITUTE JUNE-QUARTER CONSOL PROFIT 2.4 BILLION RUPEES VERSUS 1.73 BILLION RUPEES
MAX HEALTHCARE INSTITUTE JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 12.85 BILLION RUPEES VERSUS 10.67 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: MAXE.NS
(([email protected];))
Aster investors eye selling 30% stake in India biz
Company has appointed investment bank Moelis for the deal
Talks come as investors attracted by India healthcare space
By M. Sriram
MUMBAI, May 26 (Reuters) - Investors in Aster DM Healthcare ATRD.NS are in talks to sell a 30% stake in the company's India business for about $300 million, two sources with direct knowledge said, the latest potential deal in India's booming healthcare sector.
UAE-based and Mumbai-listed Aster runs 32 hospitals, 127 clinics and 521 pharmacies in India and the United Arab Emirates. The current talks are related to the India business and come just as Aster tries to demerge its Gulf business and sell a majority stake in that, Reuters reported last month.
Aster and its advisors have reached out to private equity giant KKR & Co Inc KKR.N and Max Healthcare Institute MAXE.NS - one of India's largest hospital chains - to hold preliminary talks to take up the investors' stake, the sources said.
Aster's investors considering the sale are Olympus Capital, which has a 19% stake in the company, and Mauritius-based investment firm Rimco, which holds an 12% stake.
Aster has appointed New York-based investment bank Moelis & Company to manage the deal, said the two sources, who declined to be named as the discussions are private.
Spokespersons for KKR and Olympus declined to comment, while Aster, Rimco, Moelis and Max did not respond to Reuters queries.
(Reporting by M. Sriram; Editing by Aditya Kalra and Conor Humphries)
(([email protected];; Reuters Messaging: Twitter: @followthemani))
Aster investors eye selling 30% stake in India biz
Company has appointed investment bank Moelis for the deal
Talks come as investors attracted by India healthcare space
By M. Sriram
MUMBAI, May 26 (Reuters) - Investors in Aster DM Healthcare ATRD.NS are in talks to sell a 30% stake in the company's India business for about $300 million, two sources with direct knowledge said, the latest potential deal in India's booming healthcare sector.
UAE-based and Mumbai-listed Aster runs 32 hospitals, 127 clinics and 521 pharmacies in India and the United Arab Emirates. The current talks are related to the India business and come just as Aster tries to demerge its Gulf business and sell a majority stake in that, Reuters reported last month.
Aster and its advisors have reached out to private equity giant KKR & Co Inc KKR.N and Max Healthcare Institute MAXE.NS - one of India's largest hospital chains - to hold preliminary talks to take up the investors' stake, the sources said.
Aster's investors considering the sale are Olympus Capital, which has a 19% stake in the company, and Mauritius-based investment firm Rimco, which holds an 12% stake.
Aster has appointed New York-based investment bank Moelis & Company to manage the deal, said the two sources, who declined to be named as the discussions are private.
Spokespersons for KKR and Olympus declined to comment, while Aster, Rimco, Moelis and Max did not respond to Reuters queries.
(Reporting by M. Sriram; Editing by Aditya Kalra and Conor Humphries)
(([email protected];; Reuters Messaging: Twitter: @followthemani))
May 16 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
MARCH-QUARTER CONSOL PROFIT 2.51 BILLION RUPEES VERSUS PROFIT 1.24 BILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 12.15 BILLION RUPEES VERSUS 9.37 BILLION RUPEES
DIVIDEND ONE RUPEE PER SHARE
Source text for Eikon: ID:nBSE6BLyWg
Further company coverage: MAXE.NS
(([email protected];))
May 16 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
MARCH-QUARTER CONSOL PROFIT 2.51 BILLION RUPEES VERSUS PROFIT 1.24 BILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 12.15 BILLION RUPEES VERSUS 9.37 BILLION RUPEES
DIVIDEND ONE RUPEE PER SHARE
Source text for Eikon: ID:nBSE6BLyWg
Further company coverage: MAXE.NS
(([email protected];))
- Source link: (https://bityl.co/IT4y)
- Note: Reuters has not verified this story and does not vouch for its accuracy
(Bengaluru newsroom)
(([email protected]; +91 80 6749 1310;))
- Source link: (https://bityl.co/IT4y)
- Note: Reuters has not verified this story and does not vouch for its accuracy
(Bengaluru newsroom)
(([email protected]; +91 80 6749 1310;))
April 27 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
FILED PETITION IN COURT AGAINST TOUCH HEALTHCARE, QUALITY CARE INDIA, EVERCARE GROUP MANAGEMENT
PETITION SEEKS INTERIM MEASURES OF PROTECTION, PRESERVATION OF CONTRACTUAL RIGHTS AVAILABLE TO CO PRIOR TO ARBITRATION COMMENCEMENT
Source text for Eikon: ID:nNSE3x3f6R
Further company coverage: MAXE.NS
(([email protected];))
April 27 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
FILED PETITION IN COURT AGAINST TOUCH HEALTHCARE, QUALITY CARE INDIA, EVERCARE GROUP MANAGEMENT
PETITION SEEKS INTERIM MEASURES OF PROTECTION, PRESERVATION OF CONTRACTUAL RIGHTS AVAILABLE TO CO PRIOR TO ARBITRATION COMMENCEMENT
Source text for Eikon: ID:nNSE3x3f6R
Further company coverage: MAXE.NS
(([email protected];))
April 13 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
MAX HEALTHCARE INSTITUTE LTD - COMPLETED ACQUISITION OF ADDITIONAL 34% STAKE IN EQOVA HEALTHCARE
Source text for Eikon: ID:nBSE3q6HCs
Further company coverage: MAXE.NS
(([email protected];))
April 13 (Reuters) - Max Healthcare Institute Ltd MAXE.NS:
MAX HEALTHCARE INSTITUTE LTD - COMPLETED ACQUISITION OF ADDITIONAL 34% STAKE IN EQOVA HEALTHCARE
Source text for Eikon: ID:nBSE3q6HCs
Further company coverage: MAXE.NS
(([email protected];))
More Mid Cap Ideas
See similar 'Mid' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Max Healthcare Inst. do?
Max Healthcare Institute offers healthcare services through its various facilities in Delhi and the National Capital Region, and facilities in Mohali and Bathinda. It provides services in the areas of cardiology, orthopedics and joint replacement, cancer, neurosciences, pediatrics, obstetrics and gynecology, aesthetics and reconstructive plastic surgery, internal medicine, eye and dental care, endocrinology, diabetes, obesity, ENT, metal health and behavioral sciences, physiotherapy and rehabilitation, and nuclear medicine, as well as minimal access, metabolic, and bariatric surgery.
Who are the competitors of Max Healthcare Inst.?
Max Healthcare Inst. major competitors are Apollo Hospital Ent., Fortis Healthcare, Aster DM Quality, Global Health, Narayana Hrudayalay., Krishna Inst.Medi, RainbowChildrenS Med. Market Cap of Max Healthcare Inst. is ₹97,036 Crs. While the median market cap of its peers are ₹37,891 Crs.
Is Max Healthcare Inst. financially stable compared to its competitors?
Max Healthcare Inst. seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Max Healthcare Inst. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Max Healthcare Inst. latest dividend payout ratio is 13.49% and 3yr average dividend payout ratio is 13.61%
How has Max Healthcare Inst. allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Max Healthcare Inst. balance sheet?
Balance sheet of Max Healthcare Inst. is strong. But short term working capital might become an issue for this company.
Is the profitablity of Max Healthcare Inst. improving?
Yes, profit is increasing. The profit of Max Healthcare Inst. is ₹1,457 Crs for TTM, ₹1,442 Crs for Mar 2026 and ₹1,076 Crs for Mar 2025.
Is the debt of Max Healthcare Inst. increasing or decreasing?
Yes, The net debt of Max Healthcare Inst. is increasing. Latest net debt of Max Healthcare Inst. is ₹1,522 Crs as of Mar-26. This is greater than Mar-25 when it was ₹1,142 Crs.
Is Max Healthcare Inst. stock expensive?
Max Healthcare Inst. is not expensive. Latest PE of Max Healthcare Inst. is 66.6, while 3 year average PE is 73.42. Also latest EV/EBITDA of Max Healthcare Inst. is 42.81 while 3yr average is 49.59.
Has the share price of Max Healthcare Inst. grown faster than its competition?
Max Healthcare Inst. has given lower returns compared to its competitors. Max Healthcare Inst. has grown at ~20.58% over the last 3yrs while peers have grown at a median rate of 25.84%
Is the promoter bullish about Max Healthcare Inst.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Max Healthcare Inst. is 23.71% and last quarter promoter holding is 23.71%.
Are mutual funds buying/selling Max Healthcare Inst.?
The mutual fund holding of Max Healthcare Inst. is increasing. The current mutual fund holding in Max Healthcare Inst. is 18.68% while previous quarter holding is 16.3%.